Principia Wealth Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Principia Wealth Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241	Hold	1	–	–	﹤0.01%	983
2026 Q1	$189	Hold	1	–	–	﹤0.01%	964
2025 Q4	$170	Hold	1	–	–	﹤0.01%	941
2025 Q3	$132	Hold	1	–	–	﹤0.01%	914
2025 Q2	$106	Hold	1	–	–	﹤0.01%	911
2025 Q1	$110	Hold	1	–	–	﹤0.01%	804
2024 Q4	$123	Buy	+1	New	+$118	﹤0.01%	759

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principia Wealth Advisory's JAZZ Position: Q2 2026 in Review

Principia Wealth Advisory held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 1 share worth $241. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Principia Wealth Advisory first reported a position in JAZZ in Q4 2024 and has held it in 7 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Principia Wealth Advisory held 1 share of Jazz Pharmaceuticals worth $241 as of Q2 2026.
Principia Wealth Advisory left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #983 holding.
Principia Wealth Advisory first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.